Document is current

Any future updates will be listed below

Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-022-06972-9

Published Online: 2022-12-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark